Atara Accounts Payable vs Total Liab Analysis
ATRA Stock | USD 0.67 0.02 3.08% |
Atara Biotherapeutics financial indicator trend analysis is way more than just evaluating Atara Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Atara Biotherapeutics is a good investment. Please check the relationship between Atara Biotherapeutics Accounts Payable and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
Accounts Payable vs Total Liab
Accounts Payable vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Atara Biotherapeutics Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Atara Biotherapeutics' Accounts Payable and Total Liab is 0.42. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Atara Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Atara Biotherapeutics' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Atara Biotherapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Atara Biotherapeutics' Accounts Payable and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.42 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents Atara Biotherapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Atara Biotherapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Atara Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Atara Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.At present, Atara Biotherapeutics' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 81.5 M, whereas Selling General Administrative is forecasted to decline to about 47.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 367K | 2.0M | 944K | 896.8K | Interest Income | 367K | 2.0M | 4.8M | 3.2M |
Atara Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Atara Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atara Biotherapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 342.9M | 588.1M | 468.1M | 376.4M | 165.5M | 302.7M | |
Other Current Liab | 5.7M | 40.3M | 44.9M | 50.4M | 48.5M | 51.0M | |
Total Current Liabilities | 36.7M | 82.9M | 105.8M | 78.9M | 142.2M | 149.3M | |
Total Stockholder Equity | 290.8M | 462.3M | 279.6M | 126.6M | (99.2M) | (94.3M) | |
Other Liab | 1.0M | 29.7M | 57.2M | 109.2M | 125.5M | 131.8M | |
Property Plant And Equipment Net | 68.2M | 62.8M | 79.9M | 74.3M | 58.8M | 42.2M | |
Net Debt | (60.2M) | (187.4M) | (80.6M) | (21.2M) | 31.9M | 33.5M | |
Retained Earnings | (818.0M) | (1.1B) | (1.5B) | (1.7B) | (2.0B) | (1.9B) | |
Accounts Payable | 8.0M | 7.1M | 17.4M | 6.9M | 3.7M | 6.1M | |
Cash | 74.3M | 200.4M | 106.1M | 92.9M | 26.0M | 24.7M | |
Non Current Assets Total | 70.0M | 64.8M | 83.5M | 81.3M | 63.6M | 44.3M | |
Non Currrent Assets Other | 567K | 827K | 2.4M | 7.0M | 4.8M | 5.1M | |
Other Assets | 1.8M | 14.3M | 3.6M | 7.0M | 1.0 | 0.95 | |
Cash And Short Term Investments | 259.1M | 500.7M | 371.1M | 242.8M | 51.9M | 49.3M | |
Common Stock Total Equity | 6K | 8K | 9K | 10K | 11.5K | 12.1K | |
Common Stock Shares Outstanding | 51.3M | 74.0M | 93.7M | 102.0M | 105.9M | 111.2M | |
Liabilities And Stockholders Equity | 342.9M | 588.1M | 468.1M | 376.4M | 165.5M | 302.7M | |
Non Current Liabilities Total | 15.4M | 42.9M | 82.7M | 170.9M | 122.5M | 128.6M | |
Other Current Assets | 13.9M | 21.4M | 12.6M | 10.3M | 6.2M | 8.6M | |
Other Stockholder Equity | 1.1B | 1.6B | 1.7B | 1.8B | 1.9B | 952.6M | |
Total Liab | 52.2M | 125.8M | 188.5M | 249.8M | 264.7M | 278.0M | |
Property Plant And Equipment Gross | 68.2M | 62.8M | 79.9M | 74.3M | 74.7M | 43.7M | |
Total Current Assets | 273.0M | 523.3M | 384.6M | 295.1M | 101.9M | 96.8M | |
Accumulated Other Comprehensive Income | 220K | 296K | (368K) | (2.1M) | (204K) | (214.2K) | |
Common Stock | 6K | 8K | 9K | 10K | 11K | 5.7K | |
Property Plant Equipment | 54.2M | 50.5M | 79.9M | 6.3M | 7.2M | 6.9M | |
Net Tangible Assets | 290.8M | 462.3M | 279.6M | 126.6M | 145.6M | 287.0M | |
Retained Earnings Total Equity | (818.0M) | (1.1B) | (1.5B) | (1.7B) | (1.5B) | (1.4B) | |
Short Term Investments | 184.8M | 300.3M | 265.0M | 149.9M | 25.9M | 24.6M | |
Capital Surpluse | 1.1B | 1.6B | 1.7B | 1.8B | 2.1B | 1.1B | |
Non Current Liabilities Other | 15.4M | 42.9M | 1.5M | 170.9M | 39.3M | 36.2M | |
Short Long Term Debt Total | 14.1M | 13.0M | 25.5M | 71.7M | 57.9M | 60.8M | |
Current Deferred Revenue | 21.5M | 33.5M | 40.8M | 8M | 77.8M | 81.7M | |
Net Invested Capital | 290.8M | 462.3M | 279.6M | 126.6M | (99.2M) | (94.3M) | |
Net Working Capital | 236.2M | 440.4M | 278.8M | 216.2M | (40.4M) | (38.3M) | |
Short Term Debt | 1.6M | 2.0M | 2.8M | 13.6M | 12.2M | 12.8M | |
Capital Stock | 6K | 8K | 9K | 10K | 11K | 9.0K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atara Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atara Biotherapeutics' short interest history, or implied volatility extrapolated from Atara Biotherapeutics options trading.
Pair Trading with Atara Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atara Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Atara Stock
0.49 | PAHC | Phibro Animal Health Fiscal Year End 4th of September 2024 | PairCorr |
0.44 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Atara Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atara Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atara Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atara Biotherapeutics to buy it.
The correlation of Atara Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atara Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atara Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atara Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share 0.081 | Quarterly Revenue Growth 13.457 | Return On Assets (0.62) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.